# obesity

Pfizer’s Monthly GLP‑1 Shows Promising Weight‑Loss Signal — A New Challenger in a Crowded Market

Pfizer’s long‑acting GLP‑1 candidate PF‑08653944 produced a 12.3% placebo‑adjusted mean weight loss at 28 weeks and sustained reductions after switching to monthly dosing, with mainly mild‑to‑moderate gastrointestinal side effects. The company has launched an ambitious phase 3 programme of ten trials and plans to advance full development in 2026, positioning itself to challenge incumbent GLP‑1 therapies if larger trials confirm efficacy and safety.

NeTe2026年2月3日 12:50

#Pfizer#GLP‑1#PF‑08653944

Flat lay of glucose meter and white sweets on a pink background, symbolizing diabetes awareness.

Health

Chinese Drugmaker Huadong Advances RNAi Weight‑loss Candidate into Preclinical Studies

Huadong Medicine and Suzhou Shian Biotech have confirmed a preclinical siRNA candidate aimed at an innovative weight‑loss mechanism and entered preclinical research. The move underscores China’s push into RNAi therapeutics for metabolic disease, but substantial scientific, delivery and regulatory challenges lie ahead before any clinical testing.

NeTe2026年1月29日 03:10

#siRNA#Huadong Medicine#obesity